Page 60 - The Indian Optician Digital Edition May-Junel 2022
P. 60
Hospital NHS Foundation Trust, a leading
provider of eye health services in the UK,
“Losing the sight in my left eye through dry
AMD has stopped me from doing the things I
love, like gardening, playing indoor bowls and
painting with watercolours.” She further added,
“I am thrilled to be the first to have this implant,
excited at the prospect of enjoying my hobbies
again and I truly hope that many others will
benefit from this too.”
The patient will now go through a
rehabilitation programme to learn how to
GLASSES BEING
ADJUSTED use the new vision that she has gained. The
study particularly aims at quantifying the
level of vision that is restored and the speed
at which the processing takes place. Once
the rehabilitation is complete, the patient will
potentially be able to recognise items as small
as words and be able to read again.
This study is being led by Dr. Mahi Muqit,
consultant vitreoretinal surgeon at Moorfields
Hospital, honorary clinical lecturer at the UCL
Institute of Ophthalmology, and National
Institute of Health Research (NIHR) research
investigator. He shared his thoughts on this
exceptional operation, “This ground-breaking
device offers the hope of restoration of sight
to people suffering vision loss due to dry AMD.
The success of this operation, and the evidence
gathered through this clinical study, will provide
the image. The glasses then project this focused the evidence to determine the true potential of
image as an infra-red beam through the eye to this treatment.”
the chip, which in turn converts this beam into
an electrical signal. This electrical signal passes A significantly positive impact can be
through the retina cells and the optical cells into expected in the lives of people suffering from
the brain, where it is interpreted as if it were a this condition, all thanks to this bionic chip.
natural vision. Four to six weeks after the chip is
inserted, it is tested by switching on the chip and
that is what signals the patient to see.
The patient received the Prima System
device as part of the PRIMAvera study in
France, a Europe-wide clinical trial for the new
technology, backed by the National Institute of
Health Research (NIHR) Biomedical Research
Centre at Moorfields and the UCL Institute of
Ophthalmology.
The patient further shared her journey in
a statement released by the Moorfields Eye ALL IMAGES COURTESY MOORFIELDS EYE HOSPITAL
56 THE INDIAN OPTICIAN MAY-JUNE 2022 REPORT
